Description
SWOT ANALYSIS OF OTSUKA
Otsuka
Parent Company
Otsuka Holding
Category
pharmaceutical
Sector
Health Care
Tagline/ Slogan
People creating new products for better health worldwide
Through their experience they strive to provide innovative healthcare USP solutions to contribute to healthy lives of people worldwide.
STP
Segment
Nutraceutical, CNS, Oncology related diseases
Target Group
Healthcare professionals, psychologists.
Takeda is committed to striving towards better health for patients Positioning worldwide through leading innovation in medicine.
SWOT Analysis
1. It employs over 40,000 well trained people worldwide 2. Six key molecules in the last stages of development 3. It offers wide range of solutions in the treatment of cancer ranging from anti metabolites to many new strategies Strength 4. Major player in Nutraceutical business in Japan
1. Expiry of patent of Abilify, their blockbuster drug in near future 2. They operate in low growth segment such as CNS 3. Dependence on single drug Abilify which accounts for the 50% of the sales Weakness 4. Limited presence in emerging markets
1. Growing in medical devices segment through Otsuka medical devices 2. Expansion & globalization of Soy business Opportunity 3. Increase sales channels in Asian market
Threats
1. Global economic slowdown
2. Natural disasters in Japan 3. Increasing stringency of healthcare regulations
Competition
1. Takeda pharmaceuticals 2. Abbott laboratories 3. Allergan Competitors 4. Astellas pharmaceuticals
doc_493908828.docx
SWOT ANALYSIS OF OTSUKA
Otsuka
Parent Company
Otsuka Holding
Category
pharmaceutical
Sector
Health Care
Tagline/ Slogan
People creating new products for better health worldwide
Through their experience they strive to provide innovative healthcare USP solutions to contribute to healthy lives of people worldwide.
STP
Segment
Nutraceutical, CNS, Oncology related diseases
Target Group
Healthcare professionals, psychologists.
Takeda is committed to striving towards better health for patients Positioning worldwide through leading innovation in medicine.
SWOT Analysis
1. It employs over 40,000 well trained people worldwide 2. Six key molecules in the last stages of development 3. It offers wide range of solutions in the treatment of cancer ranging from anti metabolites to many new strategies Strength 4. Major player in Nutraceutical business in Japan
1. Expiry of patent of Abilify, their blockbuster drug in near future 2. They operate in low growth segment such as CNS 3. Dependence on single drug Abilify which accounts for the 50% of the sales Weakness 4. Limited presence in emerging markets
1. Growing in medical devices segment through Otsuka medical devices 2. Expansion & globalization of Soy business Opportunity 3. Increase sales channels in Asian market
Threats
1. Global economic slowdown
2. Natural disasters in Japan 3. Increasing stringency of healthcare regulations
Competition
1. Takeda pharmaceuticals 2. Abbott laboratories 3. Allergan Competitors 4. Astellas pharmaceuticals
doc_493908828.docx